Study designs for clinical trials applied to personalised medicine: a scoping review

Cecilia Superchi, Florie Brion Bouvier, Chiara Gerardi, Montserrat Carmona, Lorena San Miguel, Luis María Sánchez-Gómez, Iñaki Imaz-Iglesia, Paula Garcia, Jacques Demotes, Rita Banzi, Raphaël Porcher, the PERMIT Group

ABSTRACT

Objective Personalised medicine (PM) allows treating patients based on their individual demographic, genomic or biological characteristics for tailoring the ‘right treatment for the right person at the right time’. Robust methodology is required for PM clinical trials, to correctly identify groups of participants and treatments. As an initial step for the development of new recommendations on trial designs for PM, we aimed to present an overview of the study designs that have been used in this field.

Design Scoping review.

Methods We searched (April 2020) PubMed, Embase and the Cochrane Library for all reports in English, French, German, Italian and Spanish, describing study designs for clinical trials applied to PM. Study selection and data extraction were performed in duplicate resolving disagreements by consensus or by involving a third expert reviewer. We extracted information on the characteristics of trial designs and examples of current applications of these approaches. The extracted information was used to generate a new classification of trial designs for PM.

Results We identified 21 trial designs, 10 subtypes and 30 variations of trial designs applied to PM, which we classified into four core categories (namely, Master protocol, Randomisation-all, Biomarker strategy and Enrichment). We found 131 clinical trials using these designs, of which the great majority were master protocols (86/131, 65.6%). Most of the trials were phase II studies (75/131, 57.2%) in the field of oncology (113/131, 86.3%). We identified 34 main features of trial designs regarding different aspects (eg, framework, control group, randomisation). The four core categories and 34 features of trial designs and examples of current applications of these approaches. The extracted information was used to generate a new classification of trial designs for PM.

Conclusions A variety of trial designs exists and is applied to PM. A new classification of trial designs is proposed to help readers to navigate the complex field of PM clinical trials.

INTRODUCTION

Personalised medicine (PM) is an evolving field, which allows treating patients by providing them a specific therapy according to their individual demographic, genomic or biological characteristics. It was defined by the European Council Conclusion on PM as ‘a medical model using characterisation of individuals’ phenotypes and genotypes (eg, molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention’.2

Many trial designs have been used to evaluate personalised treatment or interventions.3 The most common design is the enrichment design, whereby only biomarker-positive patients are randomly assigned to the targeted or control arm.4 Despite its popularity, the use of enrichment designs is recommended only when the biomarker is a perfect predictor of the response in order not to deny biomarker-negative patients a treatment they would have otherwise benefited from.5 Prospective validation of the candidate biomarker is therefore strongly recommended before applying these trials designs.

Over the last years, more complex study designs have been increasingly proposed in the field of PM. According to the Clinical Trials Facilitation and Coordination Group, a clinical trial is considered as using a complex design ‘if it has separate parts that could
constitute individual clinical trials and/or is characterised by extensive prospective adaptations such as planned additions of new Investigational Medicinal Products or new target populations. These designs are particularly efficient because they allow answering multiple clinical research questions within a single study. Examples of common complex designs are the so-called basket, umbrella and platform trials, which are frequently applied in the field of oncology. Basket trials refer to designs in which patients with heterogeneous diagnoses but with similar disease mechanisms are tested using the same targeted therapy. While, umbrella trials evaluate multiple treatment options in patient groups, which present the same disease, but with different genetic mutations. Finally, platform trials allow testing multiple targeted therapies in patients with the same disease in a perpetual manner, using interim evaluations and allowing therapies to enter or leave the trial. However, these designs are often challenging because they often require independent statistical analyses for each subprotocol, including interim analyses driving prospective adaptation with the addition of new interventions or populations, and/or termination of subprotocols based on futility or safety issues.

Numerous methodological challenges, covering many aspects of the study design (eg, randomisation, use of control arm, biomarker stratification, biomarker validation), are associated with trial designs applied to PM. The application of robust methodologies is especially important for clinical trials applied to PM to correctly control arm, biomarker stratification, biomarker validation). We conducted a scoping review following the methodological framework suggested by the Joanna Briggs Institute. The framework consists of six stages: (1) identifying the research questions, (2) identifying relevant studies, (3) selecting the studies, (4) charting the data, (5) collating, summarising and reporting results and (6) pursuing a consultation. A study protocol was published in Zenodo before conducting the review. Due to the iterative nature of scoping reviews, deviations from the protocol were expected and duly reported when occurred. We used the PRISMA-ScR (Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews) checklist to report our results.

**Study identification**

Relevant studies and documents were identified balancing feasibility with breadth and comprehensive-ness of searches. We searched PubMed, Embase and the Cochrane Library (search date: 7–8 April 2020) for all reports describing a study design for clinical trials applied to PM. Online supplemental file 1 reports the search strategies applied. We did not restrict the search to any publication type. Because many systematic and narrative reviews on trial designs applied to PM have already been published over the last years, we limited our search from 2005 to April 2020. We restricted inclusion to English, French, German Italian and Spanish languages. We searched for the grey literature on websites of existing projects about innovative clinical trials (eg, EU-PEARL) and by consulting partners of the PERMIT project.

**Eligibility criteria and deviation from the protocol**

We included all reports describing a trial design applied to PM. The operational definition of PM used in the present study is reported in box 1. Because of the extensive volume of literature related to trial designs in PM, we restricted the inclusion criteria to trial designs for phase II, III and IV. We excluded single-arm trials, which are not part of a master protocol, non-adaptive enrichment design and N-of-1 trials. We also excluded publications such as prefaces to a special issue and speaker, symposium and panel abstracts, posters and letters to the editor due to the limited information usually provided. These exclusion criteria were not specified in the protocol, but they were agreed among the authors before starting the screening process. The research question ‘What are the pros and cons of the different approaches?’ (ie, objective 3) is not reported in the present paper, and will be subject to a specific study.

**Study selection**

We exported the references retrieved from the searches into the Rayyan online tool. Duplicates were removed.
automatically using the reference manager EndNote VX9 (Clarivate Analytics, Philadelphia, USA) and manually by one author (CS). Eligible reports applying a particular trial design were retrieved from the search strategies and screened by reviewers. Five reviewers independently screened the titles and abstracts: one reviewer (CS) screened the remaining selected records, which were neither a systematic nor narrative review, only if they provided new information, which was not extracted in the previous phase. One reviewer (FBB) extracted data from all records and two reviewers (CS and MC) extracted 60% and 40% of articles, respectively. Differences in terminology were discussed between reviewers to ensure that the same trial designs were included in the same category. Disagreements were solved by consensus or by involving a third expert reviewer (RP).

It was not within the remit of this scoping review to assess the methodological quality of individual studies included in the analysis.

Collating, summarising and reporting results
We summarised the extracted data in tables and figures. Information on the definition, methodology, statistical considerations, advantages, disadvantages, utility and gaps of trial designs was extracted verbatim. Data on the examples of clinical trials adopting the different approaches were summarised using frequencies and percentages.

A researcher (CS) listed all study designs and identified the central feature(s) for each of them, which were grouped into feature domains. The initial list was reviewed by a senior statistician with expertise in designing clinical trials (RP). A final list was created and agreed on with members of the PERMIT steering committee and coauthors of the present study. The list of features was therefore based on the identified study designs and also the expertise of members of the PERMIT project.

New classification of trial designs in PM
Based on the identified trial designs and features, we proposed a new classification of trial designs for PM. Other attempts in classifying trial designs applied to PM have been proposed in the literature. However, they were limited to classifying the designs into categories or identifying the design based on a specific feature (eg, adaptive or non-adaptive trials). This new classification goes a step further, proposing a new approach in classifying the trial designs considering two variables, which are core designs and design features, into a double-entry table.

Consultation exercise
The members of the PERMIT consortium, associated partners and the PERMIT project Scientific Advisory
Figure 1: Study selection flow diagram. PERMIT, PERsonalised Medicine Trials.

We classified the trial designs into four core categories named as Master protocols, Randomise-all, Biomarker-strategy and Enrichment. Building on the definitions provided by Tajik et al and Park et al, we defined the four core categories as:

- **Master protocols**: trial design which includes multiple parallel substudies under a common infrastructure.
- **Randomise-all**: trial design where patients meeting the eligibility criteria, irrespective of their biomarker status, are randomised to either an experimental or control treatment. This category also includes those hybrid designs, which first use a Randomise-all design, and then only a specific biomarker defined subgroup is randomised to either an experimental or control treatment.
- **Biomarker-strategy**: trial design where eligible patients are randomised to either a marker-based treatment strategy or non-marker-based treatment strategy.
- **Enrichment**: trial design where eligibility is determined according to the biomarker status and patients are then randomised to either an experimental or control treatment. A specific biomarker defined subgroup (usually biomarker positives) is believed to benefit more from a treatment compared with the other subgroup (usually biomarker negatives).

An example of a study design for each core category, including its definition and methodology used, is shown in Table 1. Overall, we identified 5 trial designs, 6 subtypes and 7 variations for Master protocols, and 10 trial designs, 2 subtypes and 22 variations for Randomise-all, 5 trial designs for Biomarker-strategy and 1 trial design, 2 subtypes and 1 variation for Enrichment.

From the identified designs, we found 34 main features of trial designs in PM, which were clustered into 11 features domains (Table 2). The feature domains include the key design features that characterise a trial design for PM such as framework, model, control group, randomisation, biomarker assessment and adaptive aspects, and that should be carefully considered when designing a trial. A new classification of the trials designs for PM has been proposed and is reported in Table 3. The classification is presented in a double-entry table, which includes the main trial features on the y-axis and core categories of the trial designs on the x-axis.

**General characteristics of clinical trials in PM**

We found 131 clinical trials, which used the identified designs (online supplemental file 1). Table 4 presents the general characteristics of the identified trials.

Most trials used a basket (35/131, 26.7%), umbrella (30/131, 22.9%), platform (18/131, 13.7%) or marker stratified (15/131, 11.5%) design. The great majority of the trials were in the field of oncology (113/131, 86.3%). At the time of writing (March 2021), the recruitment status was ongoing for 48.1% (63/131) of the trials. A trial
| Core category                  | Study design example                | Study design definition                                                                                                                                                                                                 | Study design methodology                                                                                                                                                                                                 |
|-------------------------------|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Master protocols              | Platform                             | ‘A platform trial is a single histology randomized phase II clinical trial involving multiple biomarkers and multiple drugs. Rather than assuming that we know which drug is appropriate for which biomarker stratum, randomization among drugs is used in the platform trial.’ | ‘Initially the treatments are randomized with equal weights to the patients of a stratum. As data accumulates, the randomization weights change to favour assignment of drugs with higher within-stratum response rates. The endpoint used must be observed early enough to enable adoption of randomization weights.’ |
| Randomise-all                 | Biomarker-positive and overall strategies with fall-back analysis | ‘It evaluates both the treatment effect in the overall study population and in the biomarker-positive subgroup sequentially.’ | ‘In the fall-back design, we first test the overall population using the reduced significance level $\alpha_1$ and if the test is significant, we consider that the novel treatment is effective in the overall population; however, if the result is not significant then we test the treatment effect in the biomarker-positive subgroup using the level of significance $\alpha_2 = \alpha - \alpha_1$, where $\alpha$ is the overall significance level (Type I error rate). The significance levels $\alpha$ can be considered as one-sided or two-sided significance levels.’ |
| Biomarker strategy            | Biomarker-strategy design with treatment randomisation in the control arm | ‘The biomarker-strategy design with treatment randomization in the control treatment is able to inform us about whether the biomarker-based strategy is better than not only the standard treatment but also better than the experimental treatment in the overall population.’ | ‘Patients are first randomly assigned to either the biomarker-based strategy arm or to the non-biomarker-based strategy arm. Next, patients who are allocated to the non-biomarker-based strategy are again randomized either to the experimental treatment arm or to the standard treatment arm irrespective of their biomarker status. Patients who are allocated to the biomarker-based strategy and who are biomarker-positive are given the experimental treatment and patients who are biomarker-negative are given the control treatment.’ |
| Enrichment                   | Adaptive threshold sample-enrichment design | ‘It is a two-stage design in a Phase III setting(...) to adaptively modify accrual in order to broaden the targeted patient population.’ | ‘At the interim analysis stage, the treatment effect of a sample of patients ($n_1$) from the biomarker-positive subset is estimated. If an improvement is seen in the experimental treatment arm which is greater than a pre-specified threshold value (ie, the estimated treatment difference between the novel treatment arm and the control treatment arm for this subpopulation is greater than a threshold value $c$ divided by the square root of the aforementioned sample size $n_1$) the trial continues with accrual of patients from the entire biomarker-positive subgroup and additional patients are also accrued from the biomarker-negative subpopulation; otherwise the trial is stopped for futility. At the end of the trial, the treatment effect is estimated for all subpopulations. Researchers should choose the sample size $n_1$ so that a persuasive result can be reached when the first stage of the trial is completed.’ |
### Table 2 Main features of trial designs applied to personalised medicine

| Feature domains                        | Features                                      |
|----------------------------------------|-----------------------------------------------|
| Inference framework                    | Bayesian                                       |
|                                       | Frequentist                                    |
| Model†                                 | Disease progression*                          |
|                                       | Longitudinal*                                  |
|                                       | Hierarchical                                   |
| Control group                          | Common/shared†                                |
|                                       | Contemporaneous‡                              |
|                                       | Historical‡                                   |
| Randomisation                          | With treatment randomisation in both biomarker-positive and biomarker-negative subgroups |
|                                       | Without treatment randomisation in the biomarker-negative subgroup¶¶¶¶ |
|                                       | Only for patients with discordant clinical and genomic risk evaluation** |
| Randomisation in the non-biomarker based strategy arm | With treatment randomisation |
|                                       | Without treatment randomisation††††           |
|                                       | Reverse biomarker strategy††                   |
| Subgroup specific                      | Sequential subgroup specific§§                |
|                                       | Parallel subgroup specific¶¶¶                 |
| Biomarker positive and overall strategies*** | With sequential assessment |
|                                       | With parallel assessment                       |
|                                       | With fall-back analysis††††                   |
|                                       | Marker sequential test††††                    |
| Biomarker assessment                   | With biomarker assessment in the entire population |
|                                       | Without biomarker assessment in the control arm |
| Personalised medicine (PM) specific adaptive aspects §§§ | Adaptive enrichment |
|                                       | Adaptive signature                            |
|                                       | Threshold determination¶¶¶                    |
| Generic adaptive aspects              | Adding a new arm                              |
|                                       | Early stopping****                            |
|                                       | Interim analysis††††                          |
|                                       | Outcome-based adaptive randomisation          |
|                                       | Sample size reassessment                       |
|                                       | Seamless                                       |
| Treatment tailoring aspects            | Pharmacodynamic biomarker assessment after run-in phase period†††† |
|                                       | Dynamic treatment regime§§§§                   |
|                                       | PK/PD modelling                              |

*Model used for analysis. A disease progression model takes into account the patient disease state and other patient baseline characteristics for characterising patient clinical outcomes.[5] Longitudinal model permits including in the analysis the partial information of patients who have not yet reached their final outcome at an interim analysis.[6]

†A common/shared control group can be used in a trial design in which multiple treatments are being tested, instead of each treatment having its own control arm.

‡†††Patients in the common/shared control group receive a ‘Standard of care’ that may change over time or the profile of the patients enrolled on the trial may change over time, a trial design can use a contemporaneous control group meaning that the comparison of treatment’s effects may be restricted to those patients who were enrolled/randomised in the same period as those patients who were allocated to the treatment.

¶‡‡‡‡A comparison group is not available in the existing trial or substudy or at the same time but in a different setting, a trial design can use a historical control consisted of a group of individuals treated in the past.

§§ Patients in the biomarker-negative subgroup receive the control treatment.

**Only patients with discordant results (ie, either high clinical risk or low clinical risk and high genomic risk) are randomly assigned to either the control or intervention arm.

††Patients, which are randomly assigned to the non-biomarker-based strategy arm, receive the control treatment.

‡‡Patients which are randomly assigned to reverse-based strategy receive the control treatment if they are biomarker-positive and the experimental treatment if they are biomarker-negative.

§§§Study designs testing the treatment effect first in the biomarker-positive subpopulation and if the result is positive in the biomarker-negative subpopulation.

¶¶¶Study designs testing the treatment effect in both biomarker-positive and biomarker-negative subgroups simultaneously.

***Study designs testing the treatment effect in the entire study population and in the biomarker-positive subpopulation separately.

†††Study designs testing the treatment effect in the overall population and in the biomarker-positive subpopulation sequentially.

††††Study designs testing the treatment effect not only in the biomarker-positive and biomarker-negative subgroups but also in the entire population sequentially.

¶¶¶¶PM-specific adaptive aspects could be used to stratify the patients to the treatment. Generic adaptive aspects could be considered when planning a PM trial, but they could be also found in fields outside PM.

§§§§A threshold is used to divide the population into ‘biomarker positive’ and ‘biomarker negative’.

***A trial arm or clinical trial is stopped early due to pre-specified rules related to treatment efficacy and safety risk.

††††Interim analyses are pre-planned analyses, which use accumulating data in order to make an early decision or adaptation.

†††††All patients receive the new treatment for a run-in period and then are classified as either biomarker positive or negative using a pharmacodynamics biomarker.[45]

§§§§A dynamic treatment regime consists of a sequence of individually tailored therapies during the course of a treatment.

¶¶¶¶Models to suggest optimal dosage regimes of drugs for individual patients.[46]
### Table 3  Trial designs classification

| Core designs | Biomarker strategy | Enrichment | Master protocols | Randomise-all |
|--------------|--------------------|------------|------------------|---------------|
| **Design features** | | | | |
| Framework | Bayesian | Frequentist | | |
| Model | Disease progression | Longitudinal | Hierarchical | |
| Control group | Common/shared | Contemporaneous | Historical | |
| Randomisation | With treatment randomisation in both biomarker-positive and biomarker-negative subgroups | Without treatment randomisation in the biomarker-negative subgroup | Only for patients with discordant clinical and genomic risk evaluation | |
| Randomisation in the non-biomarker based strategy arm | | | | |
| Subgroup specific | Sequential subgroup specific | Parallel subgroup specific | | |
| Biomarker positive and overall strategies | With sequential assessment | With parallel assessment | With fall-back analysis | Marker sequential test |
| Biomarker assessment | With biomarker assessment in the entire population | Without biomarker assessment in the control arm | | |
| Personalised medicine specific adaptive aspects | Adaptive enrichment | Adaptive signature | Threshold determination | |
| Generic adaptive aspects | Adding a new arm | Early stopping | Interim analysis | Outcome-based adaptive randomisation |
| Sample size reassessment | Seamless | Treatment tailoring aspects | Pharmacodynamic biomarker assessment after run-in phase period | Dynamic treatment regime |
| PK/PD modelling | | | PK/PD, Pharmacokinetic/pharmacodynamic. | |
### Table 4  General characteristics of clinical trials in personalised medicine

| Trial design                                             | Clinical trial* | Recruitment status of clinical trial as for March 2021 | Disease area | Phases |
|----------------------------------------------------------|-----------------|--------------------------------------------------------|--------------|--------|
|                                                          | n=131 (%)       | Ongoing n=63 (%) | Completed n=60 (%) | n=1 (%) | Unknown‡ n=7 (%) | Cancer n=113 (%) | No cancer n=18 (%) | II n=75 (%) | II/III n=13 (%) | III n=28 (%) | IV n=12 (%) | n/a§ n=1 (%) | nft† |
| Adaptive biomarker design                                | 0 (0)           | 0 (0)         | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |         | 0 (0) |
| Adaptive parallel Simon two-stage design                 | 1 (0.8)         | 0 (0)         | 1 (1.7) | 0 (0) | 0 (0) | 1 (0.9) | 0 (0) | 1 (1.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |         | 0 (0) |
| Adaptive enrichment design                               | 4 (3.1)         | 0 (0)         | 4 (6.7) | 0 (0) | 0 (0) | 0 (0) | 4 (22.2) | 0 (0) | 0 (0) | 4 (14.3) | 0 (0) | 0 (0) |         | 0 (0) |
| Adaptive signature design                                | 0 (0)           | 0 (0)         | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |         | 0 (0) |
| Adaptive strategy for biomarker with measurement error   | 1 (0.8)         | 1 (1.6)       | 0 (0) | 0 (0) | 0 (0) | 1 (0.9) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (8.3) | 0 (0) |         | 0 (0) |
| Basket                                                   | 35 (26.7)       | 19 (30.2)     | 13 (21.7) | 0 (0) | 3 (42.9) | 34 (30.1) | 1 (5.6) | 32 (42.7) | 0 (0) | 2 (7.1) | 0 (0) | 1 (8.3) |         | 0 (0) |
| Basket of basket design                                  | 1 (0.8)         | 1 (1.6)       | 0 (0) | 0 (0) | 0 (0) | 1 (0.9) | 0 (0) | 1 (1.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |         | 0 (0) |
| Biomarker strategy design with biomarker assessment in the control arm | 3 (2.3)         | 0 (0)         | 3 (5.0) | 0 (0) | 0 (0) | 2 (1.8) | 1 (5.6) | 0 (0) | 0 (0) | 2 (7.1) | 1 (50.0) | 0 (0) |         | 0 (0) |
| Biomarker strategy design with treatment randomisation in the control arm | 0 (0)           | 0 (0)         | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |         | 0 (0) |
| Biomarker strategy design without biomarker assessment in the control arm | 4 (3.1)         | 2 (3.2)       | 2 (3.3) | 0 (0) | 0 (0) | 0 (0) | 4 (22.2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (33.3) | 0 (0) |
| Hybrid design                                            | 1 (0.8)         | 0 (0)         | 1 (1.7) | 0 (0) | 0 (0) | 1 (0.9) | 0 (0) | 0 (0) | 0 (0) | 1 (3.6) | 0 (0) | 0 (0) |         | 0 (0) |
| Marker stratified design                                 | 15 (11.5)       | 0 (0)         | 14 (23.3) | 1 (100) | 0 (0) | 15 (13.3) | 0 (0) | 0 (0) | 0 (0) | 14 (50.0) | 0 (0) | 0 (0) | 1 (100.0) |         |
| Modified biomarker strategy design                       | 3 (2.3)         | 0 (0)         | 2 (3.3) | 0 (0) | 1 (14.3) | 3 (2.7) | 0 (0) | 2 (2.7) | 0 (0) | 1 (3.6) | 0 (0) | 0 (0) |         | 0 (0) |
| Multarm multistage design                                | 7 (5.3)         | 3 (4.8)       | 3 (5.0) | 0 (0) | 1 (14.3) | 5 (4.4) | 2 (11.1) | 4 (5.3) | 2 (15.4) | 1 (3.6) | 0 (0) | 0 (0) |         | 0 (0) |
| Outcome-based adaptive randomisation design              | 4 (3.1)         | 2 (3.2)       | 2 (3.3) | 0 (0) | 0 (0) | 3 (2.7) | 1 (5.6) | 2 (2.7) | 1 (7.7) | 1 (3.6) | 0 (0) | 0 (0) |         | 0 (0) |
| Platform                                                 | 18 (13.7)       | 13 (20.6)     | 4 (6.7) | 0 (0) | 1 (14.3) | 14 (12.4) | 4 (22.2) | 11 (14.7) | 4 (30.8) | 1 (3.6) | 1 (50.0) | 1 (8.3) |         |         |
| Reverse marker biased strategy                           | 0 (0)           | 0 (0)         | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |         | 0 (0) |
| Sequential multiple assignment randomised trial          | 1 (0.8)         | 0 (0)         | 1 (1.7) | 0 (0) | 0 (0) | 0 (0) | 1 (5.6) | 0 (0) | 0 (0) | 0 (0) | 1 (8.3) | 0 (0) |         |         |
| Tandem two-stage design                                  | 1 (0.8)         | 0 (0)         | 1 (1.7) | 0 (0) | 0 (0) | 1 (0.9) | 0 (0) | 1 (1.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |         | 0 (0) |
| Umbrella                                                 | 30 (22.9)       | 20 (31.7)     | 9 (15.0) | 0 (0) | 1 (14.3) | 30 (26.5) | 0 (0) | 19 (25.3) | 6 (46.2) | 1 (3.6) | 0 (0) | 4 (33.3) | 0 (0) |         |

Continued
| Trial design                        | Clinical trial | Ongoing | Completed | nфт | Unknown‡ | Cancer | No cancer | II | II/III | III | IV | n/a§ | nфт |
|-----------------------------------|----------------|---------|-----------|-----|----------|--------|-----------|----|--------|-----|----|-------|-----|
| Umbrella-basket hybrid            | n=131 (1.5%)   | 2 (1.8) | 0 (0)     | 2 (0) | 0 (0)    | n=113  | n=18      | n=75| n=13   | n=28| n=2| n=12  | n=1|

*If the same clinical trial was labelled differently across articles, we considered the trial as example of the design reported in the paper. For instance, I-SPY 2 has been labelled as outcome-based adaptive randomisation,15 platform36 or umbrella design37 and it was considered as an example for each of those trial designs.
†Not found.
‡Unknown is used to indicate a trial status that has not been verified within the past 2 years on the ClinicalTrials.gov website.
§Not applicable is used on the ClinicalTrials.gov website to describe trials without FDA-defined phases including trials of devices or behavioural interventions.
FDA, U.S. Food and Drug Administration; n/a, Not applicable; nфт, Not found.

Table 4 Continued

We identified 16 trials (16/131, 12.2%) evaluating a PM versus a non-PM strategy, which used nine different study designs (online supplemental file 1). Three trials used a biomarker design (online supplemental file 1). This study design consists of first testing the marker status of the patient and then randomising patients to either a biomarker strategy arm or a non-biomarker strategy arm. Plus, the marker status is then measured during the follow-up period, and patients are randomised to either a biomarker strategy arm or a non-biomarker strategy arm. In the LIFT trial (NCT02498977), liver transplant recipients were randomised to either non-biomarker-based immunosuppression (IS) weaning or a biomarker-based IS weaning. ERCC1 gene expression was assessed in patients with NSCLC, which were then randomised to either platinum therapy or non-platinum therapy in the ERCC1 trial (NCT00801736).

Four trials used a biomarker strategy design without biomarker assessment in the control arm.14 19–21 This design only evaluates the biomarker status in patients who are assigned to the biomarker-based strategy.14 Patients were randomised to either the NT-pro-BNP-guided treatment arm or to usual care in the GUIDE-IT trial (NCT01685840) and either an algorithm-driven individualised haemodynamic goal-directed therapy or standard care in the iPEGASUS trial (NCT03021525). Patients with mild head injury were randomly assigned to computed tomography or observation in the hospital in the OCTOPUS trial (ISRCTN81464462) and children with a doctor's diagnosis of asthma were randomised to a PM genotype-guided treatment arm or to usual care in the PUFFIN trial (NCT03654508).

A modified strategy design, which differs from the previous strategy designs in including multiple targeted molecular profiles,22 was used in two trials.22–25 Patients with refractory cancer in the SHIVA trial (NCT01771458) were randomised to receive a molecularly targeted therapy based on a PM genotype-guided treatment arm or to control arm.22 In the OCTOPUS trial (ISRCTN81464462), patients with miliary miliary were randomised to either the NT-pro-BNP-guided treatment arm or to usual care.22

Patients with refractory cancer in the SHIVA trial (NCT01771458) were randomised to receive a molecularly targeted therapy based on a PM genotype-guided treatment arm or to control arm.22 In the OCTOPUS trial (ISRCTN81464462), patients with miliary miliary were randomised to either the NT-pro-BNP-guided treatment arm or to usual care.22

Patients with refractory cancer in the SHIVA trial (NCT01771458) were randomised to receive a molecularly targeted therapy based on a PM genotype-guided treatment arm or to control arm.22 In the OCTOPUS trial (ISRCTN81464462), patients with miliary miliary were randomised to either the NT-pro-BNP-guided treatment arm or to usual care.22
also labelled as basket trials, as well as platform trial in the case of the SHIVA trial.

One trial used an adaptive strategy design for biomarkers with measurement error. This design is used when a second cheaper biomarker exists and may be concordant with a more expensive one, which is considered the gold standard. This design was used with some modifications in the OPTIMA trial (ISRCTN42400492). Oestrogen receptor-positive, human epidermal growth factor receptor 2 (HER-2) negative breast cancer patients were randomised to be either in the control arm receiving the standard care (ie, chemotherapy and endocrine therapy) or in the treatment arm receiving the marker-guided therapy (ie, endocrine therapy). Patients in the treatment arm, which obtained a high-risk test, also received chemotherapy.

The Siyaphambili Study (NCT03500172) used a sequential multiple assignment randomised (SMART) design to compare an individualised intervention (ie, peer-led, individualised case management) or non-individualised intervention (ie, nurse-led mobile decentralised treatment programmes) to standard care (ie, South African standard of care) or combination of both interventions in women living with HIV. The SMART design allows comparing adaptive treatment strategies, which consist of a series of tailored therapies during the course of a treatment..

ProBio (NCT03903835) used an outcome-randomisation adaptive design to investigate whether a treatment based on molecular biomarker signature is more effective than standard care in men with metastatic castrate-resistant prostate cancer.

Finally, we found four trials, which evaluated a personalised versus a non-personalised strategy using a master protocol design. IMPACT II (NCT02152254) used a basket design and UPSTREAM (NCT03088059), SAFIR02_Breast (NCT02299999) and SAFIR02_Lung (NCT02117167) an umbrella design.

Gaps in the current research on clinical trials applied to PM

The results of this scoping review also allowed us to identify some gaps in the current research on clinical trials in PM. We identified three main gaps, which concern (1) the terminology used in labelling trial designs applied to PM, (2) the applications of complex innovative trial designs to fields outside of oncology and (3) the implementation of trials for evaluating PM strategy versus non-personalised strategy.

We found that trial designs are often labelled in different ways or mislabelled, despite this gap having been identified previously. An example is the Marker stratified design, which was named using 18 different labels (online supplemental file 1). We also found that a study design adopted in a clinical trial was defined differently across the literature. For instance, the I-SPY 2 trial (NCT01042379) has been labelled as outcome-based adaptive randomisation, platform or umbrella design. The I-SPY 2 is an ongoing platform trial, which studies multiple therapies in the context of breast cancer in a perpetual manner with arms being added or dropped based on current knowledge and collected data. Moreover, the study design adopted in the I-SPY 2 trial includes Bayesian adaptation algorithms in order to make decisions on estimated posterior probabilities, which are calculated at frequent interim-analysis points and response-adaptive randomisation. According to the new proposed classification, I-SPY 2 trial would be classified as Master protocol because it includes multiple substudies under the same framework, with common/shared control group, early stopping, interim analysis and outcome-based adaptive randomisation as main design features.

Moreover, another gap in the current research on PM is the lack of application of novel complex study designs to fields outside of oncology. We found that 94% (81/86) of the clinical trials which used a master protocol design were in the field of oncology.

Finally, a strong need exists for clinical trials evaluating the effectiveness of a PM strategy versus non-personalised strategy. This constitutes the third gap that we identified by mapping the evidence on clinical trials applied to PM. We found only 16 trials using nine different trial designs, which compared the two strategies.

DISCUSSION

The present study provides a broad overview and proposes a new classification of the trial designs applied to PM.

The scoping review approach was considered to be the most suitable to respond to the extensive scope of the field. Compared with systematic reviews that aim to answer specific questions, scoping reviews are used to present a broad overview of the evidence pertaining to a topic and they are useful to examine areas that are emerging, to clarify key concepts and identify gaps.

To our knowledge, this is the first study, which systematically reviews all trial designs, including complex innovative designs (ie, basket, umbrella and platform), applied to PM. Other systematic reviews have been performed on specific trial designs such as biomarker-guided adaptive trial designs, biomarker-guided non-adaptive trials designs and master protocols, or without considering master protocols in the search strategy.

We identified 21 trial designs, 10 subtypes, and 30 variations of trial designs applied to PM, which have been classified into four core categories: Master protocols, Randomise-all, Biomarker strategy and Enrichment. Randomise-all encompasses the largest number of trial designs (ie, 10 trial designs, 2 subtypes and 22 variations) and Master protocols includes those study designs which are more frequently used in clinical trials (86/131, 65.6%). A variation of the enrichment design called multistage adaptive biomarker-directed targeted (MAT) design, which combines some features of both targeted and adaptive designs, was included in the present review because it does not present the standard characteristics of a classical enrichment design but not in our classification.
In the MAT design, biomarker-positive patients are first randomised to either treatment or standard of care and interim analyses are then conducted to monitor if the primary study objectives can be achieved.

From the different approaches applied to PM, we identified 34 central features, which were combined with the four core categories in a double-entry table. The proposed table constitutes a novel manner to classify trial designs applied to PM, considering its corresponding core category and main features (eg, PM specific or generic adaptive aspects). The classification only includes features, which are strictly related to trial designs. Methods for stratification and validation of clusters in a clinical trial (eg, data-driven subgroup identification) were considered not eligible and therefore were not included. In particular, those methods were identified and described in another recent scoping review (2021).

Due to the variety and diversity of trial designs currently available, this classification provides a clearer and more accessible picture of the different trial designs available in PM, helping the readers to navigate this complex field. In addition, it could be particularly helpful for researchers as a first step for understanding the different methodological approaches available for their trials.

Also, it permits to consider all the relevant features associated with a trial design reducing confusion in reporting and labelling. We believe that this classification is more accurate and appropriate for describing a trial design applied to PM in its complexity. Moreover, it could help researchers and clinicians in using a harmonised terminology for labelling a trial.

Based on the results obtained, we identified three main gaps in the current research on clinical trials applied to PM. We found that more research is needed to evaluate the efficiency of PM approach versus non-personalised standard of care. A few clinical trials (16/131, 12.2%), using nine different study designs, were found evaluating these different strategies. In addition, these trials would be particularly relevant for health technologies assessment (HTA) bodies to evaluate the incremental benefit of PM over that of non-personalised approaches, from both a clinical and economical perspective, in those situations in which a non-personalised strategy is considered standard practice. We also need more research to apply trial designs to fields outside of oncology. This last result was consistent with what was found in a recent systematic review of master protocols. The review showed that the great majority of basket, umbrella and platform studies (76/83, 91.6%) were conducted in the field of oncology. In particular, no umbrella trials were found outside of oncology. Finally, in line with two previous systematic reviews, we found that a harmonised terminology was required because it would permit increase clarity among the variety of trial designs applied to PM.

Furthermore, current applications of the identified trial designs, together with the input of some experts in the field, helped us to identify four typologies of PM. For targeted or precision medicine, a targeted treatment, which is specific for one disease, is identified and used to treat patients with heterogeneous diagnoses but similar disease mechanisms (eg, basket trials). Stratified medicine includes trials in which patients are stratified in different clusters based on the collection of data characterised by the genotype or phenotype of the individuals (eg, adaptive signature trials). The treatment is tailored to each patient in the individualised medicine (eg, trials using pharmacokinetic models). Finally, in individualised medicine with a dynamic regime, the treatment tailored to each patient is adjusted over time based on the patient’s response (eg, SMART trials).

The new classification and the four typologies of PM clinical trials provide the basis for the future recommendations on the use of trial designs applied to PM and on trials assessing personalised versus non-PM strategy. These recommendations are strongly needed to conduct new studies within the context of PM and, consequently, have new direct high-quality evidence in the evaluation of co-dependent PM technologies.

The present study has strengths but also limitations. This is the first scoping review, which presents an overview of all trial designs applied to PM. We followed a systematic approach to map the evidence and described the process using the PRISMA-ScR guideline. However, we restricted the search strategy to the last 15 years proving a comprehensive overview rather than an exhaustive list of trial designs used in PM. In addition, by excluding single-arm trials, which are not part of a master protocol, non-adaptive enrichment design and N-of-1 trials, we might misrepresent certain study designs used for PM. Moreover, although we conducted a pilot screening for verifying the use of the same inclusion and exclusion criteria among reviewers, we cannot exclude that we did not identify some relevant publications. The information on the definition, methodology, statistical considerations, advantages, disadvantages, utility and gaps of trial designs was extracted verbatim from the included records. However, the selection of this information could be affected by the perception of the three reviewers who conducted the data extraction. Also, even if we built on existing reviews and carefully developed a comprehensive classification, all attempts at categorisation are reductive in nature, and different classification schemes could be proposed. We believe that all classifications are based on decisions, some of which are inevitably arbitrary. Nonetheless, our proposal allows separating between core design features that characterise the main objective of the trial and the patient flow, important aspects of the trial, and more accessory design features. It may form the basis of the evaluation of which design, and which features would be best suited for a given situation. For instance, HTA representatives could use our classification as a first step to better understand the design choice taken by the researchers and successively evaluate it.

The information extracted on the pros and cons of each approach (ie, objective 3) will be subject of further analysis and will be publish in a separate study due to
considerable volume of information collected. We will also explore the pros and cons of each approach in more detail, together with experts from academia and regulatory agencies, when preparing the recommendations on the use of trial designs applied to PM.

CONCLUSIONS

The findings of this scoping review show that several existing trial designs are applied to PM, which can be grouped into four core categories. A new classification has been proposed that allows describing trial designs taking into account their corresponding core category and main features. It can be used by readers to explore and better understand the complex field of PM clinical trials.

Acknowledgements The authors thank Vanna Pistotti for her assistance with search strategy development and conduct, Ines Bouajila for collaborating to the screening process and Frank Bretz, Frank Petavy and Stephen Senn for their excellent inputs and feedback.

Collaborators PERMIT Group: Antonio L Andreu, Florence Bietrix, Maria del Mar Polo-de Santos, Maddalena Fratelli, Vibeke Fosse, Enrico Gaab, Rainer Giegerath, Alexander Grundmann, Josep Maria Haro, Frank Hulstaert, Pascale Jonckheere, Setefilia Luengo Matos, Emmet McCormack, Anna Monistrol Mula, Albert Sanchez Niubo, Emanuela Oldoni, Teresa Torres.

Contributors Study conception and design: CG, CS, II-, RB and RP. Methodology: CG, CS, RB and RP. Data collection and analysis: CS, FBB, MC, II-, LMS, LMS-G and RP. Trial design classification: CS and RP. Original draft preparation: CS. Review and editing: CS, II-, LSM, LMS-G, MC, PG, RB and RP. Responsible for the overall content as guarantor: CS. All authors read and approved the final version of the manuscript. The members of the PERMIT group were involved in the preparation or revision of the joint protocol of the four scoping reviews of the PERMIT series, attended the joint workshop (consultation exercise) or contributed to one of the other scoping reviews of the PERMIT series. PG and JD coordinate the PERMIT project. JD obtained funding.

Funding This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 874825.

Competing interests None declared.

Patient and public involvement The European Patients’ Forum is a member of PERMIT project. Although not directly involved in the conduct of the scoping review, they received the draft review protocol for collecting comments and feedback.

Patient consent for publication Not applicable.

Ethics Approval This study was based entirely on a scoping review of relevant published literature and did not require an ethics approval.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository. The data set supporting the conclusions of the research reported in this paper is available in the Zenodo repository in the PERMIT community (https://zenodo.org/communities/permit-project?page=1&size=20). The data set can be accessed via Zenodo at https://zenodo.org/record/5874552#.Ye7wJmDEVQm with doi:10.5281/zenodo.5874552.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been vetted by BMJ and the relevant ethical and safety guiding principles as described in the Author Guidelines.

Purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs

Cecilia Superchi http://orcid.org/0000-0002-5375-6018
Florie Brion Bouvier http://orcid.org/0000-0001-6364-6106
Chiara Gerardi http://orcid.org/0000-0002-2499-4769
Montserrat Carmona http://orcid.org/0000-0002-4680-7745
Lorena San Miguel http://orcid.org/0000-0002-7155-7303
Luis María Sánchez-Gómez http://orcid.org/0000-0003-4358-6032
Ilkki Imaz-Iglesia http://orcid.org/0000-0002-7864-4194
Jacques Demotes http://orcid.org/0000-0002-0807-0746
Rita Banzi http://orcid.org/0000-0002-2211-3300
Raphael Porcher http://orcid.org/0000-0002-5277-4679

REFERENCES

1. Heckman-Stoddard BM, Smith JJ. Precision medicine clinical trials: defining new treatment strategies. Semin Oncol Nurs 2014;30:109–16.

2. Council of the European Union. Notices from European Union institutions, bodies, offices and agencies, OJEU, 2015.

3. Tajiik P, Zwinderman AH, Mol BW, et al. Trial designs for personalizing cancer care: a systematic review and classification. Clin Cancer Res 2013;19:4578–88.

4. Janauid P, Serghiou S, Ioannidis JPA. New clinical trial designs in the era of precision medicine: an overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treat Rev 2019;73:20–30.

5. Vivot A, Li J, Zeitoun D-J, et al. Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov. Genet Med 2016;18:796–805.

6. Clinical Trials Facilitation: procedural Coordinating Group. Recommendation paper on the initiation and conduct of complex Clinical trials. 2019.

7. Blagden SP, Bhillangham L, Brown LG, et al. Effective delivery of complex innovative design (CID) cancer trials – A consensus statement. Br J Cancer 2020;122:473–82.

8. Park JH, Siden E, Zoratti MJ, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials 2019;20:572.

9. Woodcock J, LaVange LM, Drazen JM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 2017;377:62–70.

10. Peters MDJ, Godfrey CM, Khalil H, et al. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc 2015;13:141–6.

11. Banzii R, Gerardi C, Fratelli M. Methodological approaches for personalised medicine: protocol for a series of scoping reviews., 2020. Available: https://zenodo.org/record/3770937.10.5281/zenodo.3770937

12. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 2018;169:467–73.

13. Ouazzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile APP for systematic reviews. Syst Rev 2016;5:210.

14. Antoniou M, Kolamunnage-Donna R, Jorgensen A. Biomarker-Guided Non-Adaptive trial designs in phase II and phase III: a methodological review. J Pers Med 2017;7:1.

15. Antoniou M, Jorgensen AL, Kolamunnage-Donna R. Biomarker-Guided adaptive trial designs in phase II and phase III: a methodological review. PLoS One 2016;11:e0149803.

16. Superchi C, Brion Bouvier F, Gerardi C. Data from: Scoping review of study designs for clinical trials applied to personalised medicine. Zenodo. Available: https://zenodo.org/record/5874552#.Ye7wJmDEVQM10.5281/zenodo.5874552 [Accessed 19 Jan 2022].

17. Clinicaltrials.gov. Liver Immunosuppression Free Trial (LIFT) [Internet]. Available: https://clinicaltrials.gov/ct2/show/NCT02498977.

18. Freidlin B, McShane LM, Kom EL, Randomized clinical trials with biomarkers: design issues. JNCI J Natl Cancer Inst 2010;102:152–60.

19. Ahmad T, O’Connor CM. Therapeutic implications of biomarkers in chronic heart failure. Clin Pharmacol Ther 2013;94:488–79.

20. Funcke S, Saugel B, Koch C, et al. Individualized, perioperative, hemodynamic goal-directed therapy in major abdominal surgery (iPEGASUS trial); study protocol for a randomized controlled trial. Trials 2018;19:273.

21. Vijverberg SJH, Pijnenburg MW, Hovenk AM, et al. The need for precision medicine clinical trials in childhood asthma: rationale and design of the PUFFIN trial. Pharmacogenomics 2017;18:393–401.
